Home Tags Trastuzumab deruxtecan

Tag: Trastuzumab deruxtecan

Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at Synaffix showed early in vivo...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...

Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...

HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers

Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Trastuzumab deruxtecan Launced in Japan for Patients with HER2 Positive Unresectable...

This week Daiichi Sankyo announced the launch of trastuzumab deruxtecan (Enhertu®), a HER2 directed antibody-drug conjugate (ADC), in Japan.The newly approved agent is a...
Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...

In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Netherlands Based Precision Medicines Developer Relaunches as Byondis

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) trastuzumab duocarmazine, previously known...

Advancements in the Development of ADC-technology for Cancer Treatment

In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the de developments in the technology...